Shanghai ZJ Bio-Tech , Ltd. Overview
Shanghai ZJ Bio-Tech , Ltd. (688317.SS) has a ROE of -1.99%, below the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow-1.99%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Shanghai ZJ Bio-Tech , Ltd. posts a ROE of -1.99%. That is below the Healthcare sector average of 11.15%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 11.15% is typical. Shanghai ZJ Bio-Tech , Ltd.'s -1.99% is lower that level. That is roughly 117.9% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Shanghai ZJ Bio-Tech , Ltd.'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -1.99%; use YoY and peer views to separate noise from signal.
Context for 688317.SS's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 11.15%), and (3) consistency with growth and profitability. This page covers the first two; Shanghai ZJ Bio-Tech , Ltd.'s other metric pages and overview cover the third.
Judging Shanghai ZJ Bio-Tech , Ltd. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -1.99% here, then scan peer and history charts to see if the gap is persistent.
